Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism ZG16B inhibitors(Pancreatic adenocarcinoma upregulated factor inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Epithelial Carcinoma | Discovery | SG | - | |
Pancreatic Carcinoma | Discovery | SG | - |